Real world initiation of newly funded empagliflozin and dulaglutide under special authority for patients with type 2 diabetes in New Zealand

被引：0

作者：

Lynne Chepulis ^{[1
]}

Mark Rodrigues ^{[1
]}

Han Gan ^{[2
]}

Rawiri Keenan ^{[1
]}

Tim Kenealy ^{[3
]}

Rinki Murphy ^{[3
]}

Leanne Te Karu ^{[4
]}

Jo Scott-Jones ^{[3
]}

Penny Clark ^{[5
]}

Allan Moffitt ^{[6
]}

Sara Mustafa ^{[7
]}

Ross Lawrenson ^{[1
]}

Ryan Paul ^{[1
]}

机构：

[1] University of Waikato,Waikato Medical Research Centre

[2] University of Waikato,School of Computing and Mathematical Scienes

[3] University of Auckland,Faculty of Medical and Health Sciences

[4] Health New Zealand / Te Whatu Ora Te Toka Tumai,undefined

[5] Midlands Health Network,undefined

[6] Northcare Medical Centre,undefined

[7] Procare Health Limited,undefined

[8] Health New Zealand / Te Whatu Ora Waikato,undefined

来源：

BMC Health Services Research | / 25卷 / 1期

关键词：

SGLT2i; GLP1RA; Type 2 diabetes; Health system access;

D O I：

10.1186/s12913-025-12601-3

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[31] REAL-WORLD COMPARISON OF HEALTHCARE COSTS AMONG PATIENTS WITH TYPE 2 DIABETES TREATED WITH DULAGLUTIDE VS. LIRAGLUTIDE IN THE UNITED STATES
Mody, R.
Huang, Q.
Yu, M.
Patel, H.
Zhao, R.
Grabner, M.
Lando, Fernandez L.
VALUE IN HEALTH, 2018, 21 : S80 - S80
[32] Efficacy and Safety of Empagliflozin in Patients with Type 2 Diabetes Mellitus Fasting During Ramadan: A Real-World Study from Bangladesh
Pathan, Md Faruque
Akter, Nazma
Selim, Shahjada
Saifuddin, M.
Qureshi, Nazmul Kabir
Kamrul-Hasan, A. B. M.
Hannan, Mohammad Abdul
Ahmed, Md Ashraf Uddin
Mustari, Marufa
Chakraborty, Ashish Kumar
DIABETES METABOLIC SYNDROME AND OBESITY-TARGET & THERAPY, 2022, 15 : 4011 - 4021
[33] Real-world treatment satisfaction with dulaglutide, and its influencing factors, in a Chinese population with type 2 diabetes mellitus
Guo, Lixin
Xi, Yue
Li, Li
Guo, Kunquan
Wu, Jun
Xu, Jiawei
Wang, Yihua
Wu, Guangyu
Si, Si
DIABETES OBESITY & METABOLISM, 2024, 26 (07): : 2979 - 2983
[34] Association of Dulaglutide Initiation Timing With Treatment Patterns and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus in the United States
Hoog, Meredith
Smith, Joseph L.
Yu, Maria
Peleshok, Jennifer
Mody, Reema
Grabner, Michael
CLINICAL THERAPEUTICS, 2022, 44 (06) : 873 - +
[35] Effect of Dulaglutide Therapy Initiation on the Course of Coronavirus Infection and the Dynamics of Inflammatory Markers in Hospitalized Patients with Type 2 Diabetes
Markova, Tatiana
Stas, Mukhamed
Anchutina, Anastasia
DIABETES, 2023, 72
[36] Cardiovascular events and mortality in patients newly diagnosed with type 2 diabetes with and without multimorbidity: a real world observational study
Coles, B.
Zaccardi, F.
Hvid, C.
Davies, M. J.
Khunti, K.
DIABETOLOGIA, 2020, 63 (SUPPL 1) : S448 - S448
[37] Real-world Impact of 3 and 4.5 mg Doses of Dulaglutide on Weight and Hemoglobin A1c in Patients With Type 2 Diabetes Mellitus
Duong, Amy
Heacock, Samantha
Amering, Sarah
Brennan, Lillian
Venci, Jineane
Acquisto, Nicole M.
ANNALS OF PHARMACOTHERAPY, 2024, 58 (06) : 589 - 597
[38] Factors associated with initiation of antihyperglycaemic medication in UK patients with newly diagnosed type 2 diabetes
Alan J Sinclair
Charles M Alexander
Michael J Davies
Changgeng Zhao
Panagiotis Mavros
BMC Endocrine Disorders, 12
[39] Factors associated with initiation of antihyperglycaemic medication in UK patients with newly diagnosed type 2 diabetes
Sinclair, Alan J.
Alexander, Charles M.
Davies, Michael J.
Zhao, Changgeng
Mavros, Panagiotis
BMC ENDOCRINE DISORDERS, 2012, 12
[40] Dulaglutide as an Add-on to Insulin in Type 2 Diabetes; Clinical Efficacy and Parameters Affecting the Response in Real-World Practice
Lee, Jiwoo
Cho, Yun Kyung
Kim, Hwi Seung
Jung, Chang Hee
Park, Joong-Yeol
Lee, Woo Je
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2019, 12 : 2745 - 2753

← 1 2 3 4 5 →